[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636156":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":11,"locations":34,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sinocelltech Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SCTB35 and Lenalidomide","EXPERIMENTAL",null,[13,14],"Drug: SCTB35 injection","Drug: Lenalidomide",{"label":16,"type":17,"description":11,"interventionNames":18},"Rituximab and Lenalidomide","ACTIVE_COMPARATOR",[19,14],"Drug: Rituximab",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","SCTB35 injection","SCTB35 will be subcutaneously administered at a dose as specified",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Rituximab","Intravenous Infusion",[16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Lenalidomide","Oral Capsules",[16,9],[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636156",false,"NCT07562022","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","Inclusion Criteria:\n\n* Age 18-80 years old\n* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria\n* Relapsed or refractory (R\u002FR) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy\n* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion\n* A measurable or evaluable disease at the time of enrolment\n* ECOG PS 0-2\n* Adequate organ function and bone marrow function\n* Expected survival ≥ 6 months\n\nExclusion Criteria:\n\n* Documented refractoriness to lenalidomide.\n* Have lenalidomide exposure within 12 months prior to randomization","ALL","18 Years","80 Years",{"count":59,"type":60},93,"ESTIMATED","INTERVENTIONAL",[63],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).",[66],"Follicular Lymphoma (FL)","NOT_YET_RECRUITING","2026-04-24",{"date":70,"type":71},"2026-05-01","ACTUAL",{"date":73,"type":60},"2026-05",{"date":75,"type":60},"2029-06",{"name":5,"class":6},1]